Physician profile
Margaret Webb
NPI 1962847384
$3,637.15
in general payments reported to CMS, 2019-2025
32 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what 96% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $172 · 2021: $594 · 2022: $342 · 2023: $216 · 2024: $486 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.61 |
| Education | $222.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $551.12 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $525.83 | 2021-2025 | |
| Janssen Biotech, INC. | $408.11 | 2020-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $404.06 | 2024-2025 | Dupixent |
| Leo Pharma INC. | $234.78 | 2024-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $170.67 | 2023-2025 | |
| Incyte Corporation | $126.00 | 2021 | |
| Mallinckrodt Hospital Products INC. | $108.75 | 2025 | Acthar |
| Amryt Pharma Holdings LTD | $105.63 | 2022 | |
| Organon LLC | $93.03 | 2025 | Vtama |
| Amgen INC. | $92.33 | 2025 | Otezla |
| Pfizer INC. | $91.95 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $77.91 | 2019 | |
| Lilly USA, LLC | $71.62 | 2024-2025 | Ebglyss, Taltz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $67.41 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $50.30 | 2020 | |
| Sun Pharmaceutical Industries INC. | $48.82 | 2025 | |
| Melinta Therapeutics, LLC | $47.84 | 2019 | |
| Kyowa Kirin, INC. | $37.01 | 2023 | Poteligeo |
| Galderma Laboratories, L.P. | $35.82 | 2025 | Nemluvio |
| Helsinn Therapeutics (U.S.), INC. | $33.54 | 2021-2022 | |
| Convatec INC. | $32.76 | 2025 | |
| Alexion Pharmaceuticals, INC. | $32.70 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.10 | 2019-2020 | |
| Ucb, INC. | $22.22 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.31 | 2022 | |
| Seagen INC. | $20.59 | 2021 | |
| Arcutis Biotherapeutics, INC. | $20.28 | 2025 | Zoryve |
| Almirall LLC | $19.34 | 2024 | Klisyri |
| Stemline Therapeutics INC. | $17.72 | 2022 | |
| Novo Nordisk INC | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.